TAIWAN LIPOSOME/S’s (TLC) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of TAIWAN LIPOSOME/S (NASDAQ:TLC) in a report released on Thursday morning, AnalystRatings.com reports. The brokerage currently has a $11.00 price target on the stock.

Several other equities research analysts have also recently weighed in on the company. Zacks Investment Research cut TAIWAN LIPOSOME/S from a buy rating to a hold rating in a research report on Wednesday, January 29th. ValuEngine raised TAIWAN LIPOSOME/S from a hold rating to a buy rating in a research report on Tuesday, December 31st. Finally, Cantor Fitzgerald reduced their price objective on TAIWAN LIPOSOME/S from $11.00 to $10.00 and set an overweight rating for the company in a research report on Wednesday. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average price target of $9.00.

Shares of TLC traded up $0.17 during trading hours on Thursday, reaching $5.40. The company’s stock had a trading volume of 732 shares, compared to its average volume of 1,788. The company has a 50 day moving average of $5.38 and a two-hundred day moving average of $5.23. TAIWAN LIPOSOME/S has a 1-year low of $4.61 and a 1-year high of $8.54. The firm has a market cap of $200.24 million, a price-to-earnings ratio of -9.64 and a beta of 0.78. The company has a quick ratio of 2.01, a current ratio of 2.01 and a debt-to-equity ratio of 0.14.

An institutional investor recently raised its position in TAIWAN LIPOSOME/S stock. Millennium Management LLC increased its holdings in shares of TAIWAN LIPOSOME/S (NASDAQ:TLC) by 564.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 92,915 shares of the company’s stock after purchasing an additional 112,915 shares during the period. Millennium Management LLC owned approximately 0.29% of TAIWAN LIPOSOME/S worth $474,000 at the end of the most recent quarter. 2.11% of the stock is currently owned by institutional investors and hedge funds.


Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). Its BioSeizer lipid formulation technology enables pharmacokinetic (PK) control and local sustained release of APIs at the site of disease or injury; and NanoX targeted delivery technology enables prolonged PK profiles and enhanced distribution of liposome-encapsulated APIs at the desired site.

Featured Story: How can investors find ex-dividend dates?

Receive News & Ratings for TAIWAN LIPOSOME/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TAIWAN LIPOSOME/S and related companies with MarketBeat.com's FREE daily email newsletter.